Growth hormone-releasing hormone analog pharmacology and endocrine applications

study092

10.1016/j.clinthera.2007.01.014

Clinical Therapeutics

review article

Review of long-acting GHRH analogs including CJC-1295 and endocrine applications.

Long-acting GHRH analogs can meaningfully augment GH/IGF-1 exposure with intermittent dosing.

cjc-1295-ipamorelin|sermorelin|tesamorelin

hormone-optimization

apex-stack|gh-optimization-stack

cjc-1295-vs-ipamorelin|tesamorelin-vs-sermorelin

published

‹ CJC-1295, a long-acting GHRH analog, stimulates GH and IGF-1 secretion in adults

Somatropin treatment in adults with GH deficiency: meta-analysis of body composition outcomes ›